According to the results of a study published in the Journal of Clinical Oncology a bone scan index (BSI) can assess response to treatment and predict survival in metastatic hormone-refractory prostate cancer. Men who have castrate resistant or metastatic hormone-refractory prostate cancer that no longer responds to hormonal therapy and has spread to distant sites [...]
Amgen announced that the U.S. Food and Drug Administration (FDA) has approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in men receiving androgen deprivation therapy (ADT) for non-metastatic prostate cancer. Men receiving ADT are at high risk for developing fractures, including vertebral fractures, which can cause paralysis. "Bone loss [...]
A recent meeting of an FDA advisory committee has asked wants the FDA to limit the duration of bisphosphonate therapy for treatment of osteoporosis, but the committee could not agree on a time limit to recommend. […]
I am in Orlando Florida attending the Department of Defense Impact Conference for the Prostate Cancer Research Program (PCRP) This DOD program is among the largest funders of prostate cancer research in the world and what is important is that the funding is designed to move research ideas that are specifically designed to have a [...]
Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against [...]
We all know that one of the common problems many of us will confront when fighting prostate cancer is experiencing bone fractures. Somtimes these fractures happen for little or no obvious cause. Why are bone fractures, especially spontaneous fractures (without any evident reason) so common in prostate cancer? […]
Many men with metastatic prostate cancer will suffer compression fractures in their spine. Since the spine is one of the most common sites for metastatic spread of the disease, the vertebrae often become brittle and at a very high risk for fractures. Hormone therapy and radiation therapy can also have a weakening effect on bone [...]
An article published Online First and in an upcoming edition of The Lancet Oncology reports that an oral bisphosphonate, sodium clodronate, improves overall survival in men with advanced prostate cancer. However, it does not reduce the risk of death in men with localized disease. These are the final results of the MRC PR05 and MRC [...]
Pamidronate and zoledronic acid (bisphosphonates) are a mainstay in the treatment of men with advanced prostate cancer as well as for breast cancer survivors for the prevention of skeletal-related events (SREs). There have been many clinical trials comparing the efficacy and side effect profiles between pamidronate and zoledronic acid among men with advanced prostate cancer. [...]
It has been clearly shown that androgen deprivation therapy (ADT) for the treatment of prostate cancer leads to loss of bone mineral density (BMD) and increased fracture risk. More importantly, loss of BMD shortens survival time. (see my post of December 27, 2009 “On the Horizon – Dasatinib A Drug to Inhibit the growth of [...]
